<font color="blue">Safety_3</font> <font color="blue">,_3</font> <font color="blue">tolerability_3</font> <font color="blue">,_3</font> <font color="blue">and_3</font> <font color="blue">immunogenicity_3</font> after 1 and 2 doses of zoster vaccine in healthy adults ≥60 years of age . 
<br>
<br> BACKGROUND <font color="blue">Incidence_1</font> <font color="blue">and_1</font> <font color="blue">severity_1</font> of herpes zoster ( HZ ) and postherpetic neuralgia increase with age , associated with age - related decrease in immunity to varicella - zoster virus ( VZV ) . One dose of zoster vaccine ( ZV ) has demonstrated <font color="blue">substantial_1</font> <font color="blue">protection_1</font> <font color="blue">against_1</font> <font color="blue">HZ_1</font> <font color="blue">;_1</font> this study examined <font color="blue">impact_2</font> <font color="blue">of_1</font> <font color="blue">a_1</font> <font color="blue">second_1</font> <font color="blue">dose_1</font> <font color="blue">of_1</font> <font color="blue">ZV_1</font> <font color="blue">._1</font> 
<br> METHODS Randomized , double - blind , multicenter study with 210 subjects ≥60 years old <font color="blue">compared_1</font> <font color="blue">immunity_2</font> <font color="blue">and_2</font> <font color="blue">safety_2</font> <font color="blue">profiles_2</font> <font color="blue">after_1</font> <font color="blue">one_1</font> <font color="blue">and_1</font> <font color="blue">two_1</font> <font color="blue">doses_1</font> <font color="blue">of_1</font> <font color="blue">ZV_1</font> <font color="blue">,_1</font> separated by 6 weeks , vs. placebo . <font color="blue">Immunogenicity_3</font> <font color="blue">was_2</font> <font color="blue">evaluated_2</font> <font color="blue">using_1</font> <font color="blue">VZV_2</font> <font color="blue">interferon_2</font> <font color="blue">-_2</font> <font color="blue">gamma_2</font> <font color="blue">(_2</font> <font color="blue">IFN-γ_2</font> <font color="blue">)_2</font> <font color="blue">enzyme_2</font> <font color="blue">-_2</font> <font color="blue">linked_2</font> <font color="blue">immunospot_2</font> <font color="blue">(_2</font> <font color="blue">ELISPOT_2</font> <font color="blue">)_2</font> <font color="blue">assay_2</font> <font color="blue">and_1</font> <font color="blue">VZV_2</font> <font color="blue">glycoprotein_2</font> <font color="blue">enzyme_2</font> <font color="blue">-_2</font> <font color="blue">linked_2</font> <font color="blue">immunosorbent_2</font> <font color="blue">antibody_2</font> <font color="blue">(_2</font> <font color="blue">gpELISA_2</font> <font color="blue">)_2</font> <font color="blue">assay_2</font> <font color="blue">._2</font> <font color="blue">Adverse_1</font> <font color="blue">experiences_1</font> <font color="blue">(_1</font> <font color="blue">AEs_1</font> <font color="blue">)_1</font> were recorded on a standardized <font color="blue">Vaccination_1</font> <font color="blue">Report_1</font> <font color="blue">Card_1</font> <font color="blue">._1</font> <font color="blue">
<br>_1</font> <font color="blue">RESULTS_1</font> <font color="blue">No_1</font> <font color="blue">serious_1</font> <font color="blue">vaccine_2</font> <font color="blue">-_2</font> <font color="blue">related_2</font> <font color="blue">AEs_2</font> <font color="blue">occurred_1</font> <font color="blue">._1</font> <font color="blue">VZV_3</font> <font color="blue">IFN-γ_3</font> <font color="blue">ELISPOT_3</font> <font color="blue">geometric_3</font> <font color="blue">mean_3</font> <font color="blue">count_3</font> <font color="blue">(_3</font> <font color="blue">GMC_3</font> <font color="blue">)_3</font> <font color="blue">of_2</font> <font color="blue">spot_3</font> <font color="blue">-_3</font> <font color="blue">forming_3</font> <font color="blue">cells_3</font> <font color="blue">per_3</font> <font color="blue">10(6_3</font> <font color="blue">)_3</font> <font color="blue">peripheral_3</font> <font color="blue">blood_3</font> <font color="blue">mononuclear_3</font> <font color="blue">cells_3</font> <font color="blue">increased_1</font> in the ZV group from 16.9 prevaccination to 49.5 and 32.8 at 2 and 6 weeks postdose 1 , respectively . Two weeks , 6 weeks and 6 months postdose 2 , <font color="blue">GMC_2</font> was 44.3 , 42.9 , and 36.5 , respectively . <font color="blue">GMC_2</font> in the placebo group did not change during the study . The <font color="blue">peak_2</font> <font color="blue">ELISPOT_2</font> <font color="blue">response_2</font> occurred ∼2 weeks after each ZV dose . The <font color="blue">gpELISA_2</font> <font color="blue">geometric_2</font> <font color="blue">mean_2</font> <font color="blue">titers_2</font> <font color="blue">(_2</font> <font color="blue">GMTs_2</font> <font color="blue">)_2</font> in the ZV group were <font color="blue">higher_1</font> than in the placebo group at 6 weeks after each dose . <font color="blue">Correlation_2</font> <font color="blue">between_1</font> <font color="blue">the_1</font> <font color="blue">IFN-γ_2</font> <font color="blue">ELISPOT_2</font> <font color="blue">and_2</font> <font color="blue">gpELISA_2</font> <font color="blue">assays_2</font> <font color="blue">was_1</font> <font color="blue">poor_1</font> <font color="blue">._1</font> 
<br> CONCLUSIONS <font color="blue">ZV_1</font> was generally <font color="blue">well_2</font> <font color="blue">-_2</font> <font color="blue">tolerated_2</font> <font color="blue">and_2</font> <font color="blue">immunogenic_2</font> in adults ≥60 years old . <font color="blue">A_1</font> <font color="blue">second_1</font> <font color="blue">dose_1</font> <font color="blue">of_1</font> <font color="blue">ZV_1</font> <font color="blue">was_1</font> <font color="blue">generally_2</font> <font color="blue">safe_2</font> <font color="blue">,_2</font> <font color="blue">but_1</font> <font color="blue">did_1</font> <font color="blue">not_1</font> <font color="blue">boost_2</font> <font color="blue">VZV_2</font> <font color="blue">-_2</font> <font color="blue">specific_2</font> <font color="blue">immunity_2</font> <font color="blue">beyond_1</font> <font color="blue">levels_1</font> <font color="blue">achieved_1</font> <font color="blue">postdose_1</font> <font color="blue">1_1</font> <font color="blue">._1</font>